# Freenome

> AI-driven multi-cancer early detection from a routine blood draw.

## Why it is interesting

Freenome is a high-stakes diagnostics AI company — clinical validation and FDA clearance are the whole game, with $590M+ raised including Roche strategic investment.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences, ai-ml
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series D (Dec 2021): $300M with Bain Capital Life Sciences (/fund/bain-capital-ventures) and a16z Life Sciences Growth Fund (/fund/andreessen-horowitz) (Freenome press)
- Roche invested $290M (Jan 2022) as strategic partner; Roche Venture Fund not in VCT directory

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/bain-capital-ventures

---
Source: https://venturecapitaltracker.com/startup/freenome